Children LTBI
Conditions
Keywords
Children, LTBI, Intervention
Brief summary
The management of latent Mycobacterium tuberculosis infection is a new priority action for the WHO End Tuberculosis (TB) Strategy. However, national guidelines on latent tuberculosis infection testing and treatment have not yet been developed in children of China. Here, we present the results from the 3-year follow-up of a study that aimed to track the development of active disease in individuals with latent tuberculosis infection, identify priority populations for latent infection management, and explore the most suitable latent infection diagnostic approach.
Detailed description
1\. Baseline analysis of a population-based, multicentre, prospective cohort study 1. A baseline survey of a population-based, multicentre, prospective cohort study were took in children (≤18). 2. Eligible participants were identifi ed by door-to-door survey with a household sampling design. 3. Participants were screened for active tuberculosis and history of tuberculosis then used a tuberculin skin test and an interferon-γ release assay (QuantiFERON \[QFT\]) to test for latent infection. 2\. Incidence of active tuberculosis in individuals with latent tuberculosis infection in children of China under different treatment regimens 1. Individuals who had tuberculosis infection at baseline (QFT-positivity or TST tuberculin reaction size \[induration\] of ≥10 mm) were divided and treatment with different therapeutic schedule. 2. Follow-up study were conducted to assess the proportion of latent TB infection converted to active TB
Interventions
DRUGINH、RFT
6INH 10mg/kg 3INH+RFT 15mg/kg
Sponsors
Beijing Children's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
1 Days to 18 Years
Healthy volunteers
No
Inclusion criteria
* Children (0-18 years old). * Children with QFT-positive or TST induration ≥10 mm).
Exclusion criteria
* Patients are allergic to anti-tuberculsis drugs. * Parents and/or guardians do not agree to participate in this study. * Participants with active tuberculosis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Morbidity | During the 2 year follow-up study | Percentage of latent TB infections converted to active TB |
| Proportion of adverse reactions | During the 2 year follow-up study | The incidence of adverse reactions in different treatment regimens |
| Proportion of lost to follow-up | During the 2 year follow-up study | The proportion of lost to follow-up in different treatment regimens |
Countries
China
Contacts
Primary ContactA-Dong Shen, Master
Outcome results
None listed